- Home
- UVE vs AVTX Comparison
UVE vs AVTX Comparison
Compare UVE & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UVE | AVTX |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 982.5M |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | UVE | AVTX |
|---|---|---|
| Price | $42.32 | $19.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $40.00 | ★ $40.57 |
| AVG Volume (30 Days) | 187.1K | ★ 729.8K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ 214.43 | 72.07 |
| EPS | ★ 3.93 | N/A |
| Revenue | ★ $1,603,915,000.00 | $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.88 | N/A |
| P/E Ratio | $10.77 | ★ N/A |
| Revenue Growth | 5.48 | ★ 2312.27 |
| 52 Week Low | $24.03 | $8.65 |
| 52 Week High | $45.15 | $24.27 |
Technical Indicators
Market Signals| Indicator | UVE | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.15 | 55.53 |
| Support Level | $41.88 | $17.40 |
| Resistance Level | $43.68 | $20.68 |
| Average True Range (ATR) | 1.04 | 1.06 |
| MACD | -0.26 | 0.04 |
| Stochastic Oscillator | 25.18 | 66.12 |
Price Performance
Historical ComparisonAbout UVE UNIVERSAL INSURANCE HOLDINGS INC
Universal Insurance Holdings Inc is an insurance holding company. Through its subsidiaries, the company mainly offers property and casualty insurance and value-added insurance services. It develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners lines of business and performs all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The group offers the following types of personal residential insurance: homeowners, renters/tenants, condo unit owners, and dwelling/fire, through an independent agent network and online distribution channels across multiple states in the United States of America.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.